1. Home
  2. EVC vs FHTX Comparison

EVC vs FHTX Comparison

Compare EVC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVC
  • FHTX
  • Stock Information
  • Founded
  • EVC 1996
  • FHTX 2015
  • Country
  • EVC United States
  • FHTX United States
  • Employees
  • EVC N/A
  • FHTX N/A
  • Industry
  • EVC Broadcasting
  • FHTX Medicinal Chemicals and Botanical Products
  • Sector
  • EVC Industrials
  • FHTX Health Care
  • Exchange
  • EVC Nasdaq
  • FHTX Nasdaq
  • Market Cap
  • EVC 229.5M
  • FHTX 237.4M
  • IPO Year
  • EVC 2000
  • FHTX 2020
  • Fundamental
  • Price
  • EVC $2.20
  • FHTX $5.23
  • Analyst Decision
  • EVC Hold
  • FHTX Strong Buy
  • Analyst Count
  • EVC 1
  • FHTX 6
  • Target Price
  • EVC $1.75
  • FHTX $13.17
  • AVG Volume (30 Days)
  • EVC 230.5K
  • FHTX 163.3K
  • Earning Date
  • EVC 03-04-2025
  • FHTX 03-06-2025
  • Dividend Yield
  • EVC 9.09%
  • FHTX N/A
  • EPS Growth
  • EVC N/A
  • FHTX N/A
  • EPS
  • EVC N/A
  • FHTX N/A
  • Revenue
  • EVC $1,146,066,000.00
  • FHTX $25,515,000.00
  • Revenue This Year
  • EVC N/A
  • FHTX N/A
  • Revenue Next Year
  • EVC N/A
  • FHTX $8.30
  • P/E Ratio
  • EVC N/A
  • FHTX N/A
  • Revenue Growth
  • EVC 122.49
  • FHTX N/A
  • 52 Week Low
  • EVC $1.33
  • FHTX $3.86
  • 52 Week High
  • EVC $3.92
  • FHTX $10.25
  • Technical
  • Relative Strength Index (RSI)
  • EVC 46.64
  • FHTX 52.39
  • Support Level
  • EVC $2.14
  • FHTX $3.89
  • Resistance Level
  • EVC $2.30
  • FHTX $6.27
  • Average True Range (ATR)
  • EVC 0.08
  • FHTX 0.59
  • MACD
  • EVC 0.01
  • FHTX 0.11
  • Stochastic Oscillator
  • EVC 50.00
  • FHTX 48.38

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: